Cohort profile: The Swedish Inception Cohort in inflammatory bowel disease (SIC-IBD)

Cohort profile: The Swedish Inception Cohort in inflammatory bowel disease (SIC-IBD) | medRxiv /* */ /* */ <!-- <!-- /*! * yepnope1.5.4 * (c) WTFPL, GPLv2 */ (function(a,b,c){function d(a){return"[object Function]"==o.call(a)}function e(a){return"string"==typeof a}function f(){}function g(a){return!a||"loaded"==a||"complete"==a||"uninitialized"==a}function h(){var a=p.shift();q=1,a?a.t?m(function(){("c"==a.t?B.injectCss:B.injectJs)(a.s,0,a.a,a.x,a.e,1)},0):(a(),h()):q=0}function i(a,c,d,e,f,i,j){function k(b){if(!o&&g(l.readyState)&&(u.r=o=1,!q&&h(),l.onload=l.onreadystatechange=null,b)){"img"!=a&&m(function(){t.removeChild(l)},50);for(var d in y[c])y[c].hasOwnProperty(d)&&y[c][d].onload()}}var j=j||B.errorTimeout,l=b.createElement(a),o=0,r=0,u={t:d,s:c,e:f,a:i,x:j};1===y[c]&&(r=1,y[c]=[]),"object"==a?l.data=c:(l.src=c,l.type=a),l.width=l.height="0",l.onerror=l.onload=l.onreadystatechange=function(){k.call(this,r)},p.splice(e,0,u),"img"!=a&&(r||2===y[c]?(t.insertBefore(l,s?null:n),m(k,j)):y[c].push(l))}function j(a,b,c,d,f){return q=0,b=b||"j",e(a)?i("c"==b?v:u,a,b,this.i++,c,d,f):(p.splice(this.i++,0,a),1==p.length&&h()),this}function k(){var a=B;return a.loader={load:j,i:0},a}var l=b.documentElement,m=a.setTimeout,n=b.getElementsByTagName("script")[0],o={}.toString,p=[],q=0,r="MozAppearance"in l.style,s=r&&!!b.createRange().compareNode,t=s?l:n.parentNode,l=a.opera&&"[object Opera]"==o.call(a.opera),l=!!b.attachEvent&&!l,u=r?"object":l?"script":"img",v=l?"script":u,w=Array.isArray||function(a){return"[object Array]"==o.call(a)},x=[],y={},z={timeout:function(a,b){return b.length&&(a.timeout=b[0]),a}},A,B;B=function(a){function b(a){var a=a.split("!"),b=x.length,c=a.pop(),d=a.length,c={url:c,origUrl:c,prefixes:a},e,f,g;for(f=0;f<d;f++)g=a[f].split("="),(e=z[g.shift()])&&(c=e(c,g));for(f=0;f<b;f++)c=x[f](c);return c}function g(a,e,f,g,h){var i=b(a),j=i.autoCallback;i.url.split(".").pop().split("?").shift(),i.bypass||(e&&(e=d(e)?e:e[a]||e[g]||e[a.split("/").pop().split("?")[0]]),i.instead?i.instead(a,e,f,g,h):(y[i.url]?i.noexec=!0:y[i.url]=1,f.load(i.url,i.forceCSS||!i.forceJS&&"css"==i.url.split(".").pop().split("?").shift()?"c":c,i.noexec,i.attrs,i.timeout),(d(e)||d(j))&&f.load(function(){k(),e&&e(i.origUrl,h,g),j&&j(i.origUrl,h,g),y[i.url]=2})))}function h(a,b){function c(a,c){if(a){if(e(a))c||(j=function(){var a=[].slice.call(arguments);k.apply(this,a),l()}),g(a,j,b,0,h);else if(Object(a)===a)for(n in m=function(){var b=0,c;for(c in a)a.hasOwnProperty(c)&&b++;return b}(),a)a.hasOwnProperty(n)&&(!c&&!--m&&(d(j)?j=function(){var a=[].slice.call(arguments);k.apply(this,a),l()}:j[n]=function(a){return function(){var b=[].slice.call(arguments);a&&a.apply(this,b),l()}}(k[n])),g(a[n],j,b,n,h))}else!c&&l()}var h=!!a.test,i=a.load||a.both,j=a.callback||f,k=j,l=a.complete||f,m,n;c(h?a.yep:a.nope,!!i),i&&c(i)}var i,j,l=this.yepnope.loader;if(e(a))g(a,0,l,0);else if(w(a))for(i=0;i (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0];var j=d.createElement(s);var dl=l!='dataLayer'?'&l='+l:'';j.src='//www.googletagmanager.com/gtm.js?id='+i+dl;j.type='text/javascript';j.async=true;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-P4HH5NV'); Skip to main content Home About Submit ALERTS / RSS Search for this keyword Advanced Search Cohort profile: The Swedish Inception Cohort in inflammatory bowel disease (SIC-IBD) View ORCID Profile Benita Salomon , View ORCID Profile Olle Grännö , Daniel Bergemalm , Hans Strid , Adam Carstens , Henrik Hjortswang , Maria Ling Lundström , Jóhann P Hreinsson , Sven Almer , Francesca Bresso , Carl Eriksson , Olof Grip , André Blomberg , Jan Marsal , Niloofar Nikaein , Shoaib Bakhtyar , Carl Mårten Lindqvist , Elisabet Hultgren Hörnquist , Maria K Magnusson , Åsa V Keita , Mauro D’Amato , Dirk Repsilber , Lena Öhman , Johan D Söderholm , Marie Carlson , Charlotte R H Hedin , Robert Kruse , View ORCID Profile Jonas Halfvarson doi: https://doi.org/10.1101/2025.01.12.25320315 Benita Salomon 1 School of Medical Sciences, Faculty of Medicine and Health, Örebro University , Örebro, Sweden Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Benita Salomon Olle Grännö 2 Department of Laboratory Medicine, Clinical Microbiology, Faculty of Medicine and Health, Örebro University , Örebro, Sweden Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Olle Grännö Daniel Bergemalm 3 Department of Gastroenterology, Faculty of Medicine and Health, Örebro University , Örebro, Sweden Find this author on Google Scholar Find this author on PubMed Search for this author on this site Hans Strid 4 Centre for Digestive Health, Department of Gastroenterology, Dermatovenereology and Rheumatology, Karolinska University Hospital , Stockholm, Sweden Find this author on Google Scholar Find this author on PubMed Search for this author on this site Adam Carstens 5 Department of Internal Medicine, Ersta Hospital , Stockholm, Sweden 6 Department of Medicine Huddinge, Karolinska Institute , Stockholm, Sweden Find this author on Google Scholar Find this author on PubMed Search for this author on this site Henrik Hjortswang 7 Department of Gastroenterology, County Council of Östergötland, Department of Clinical and Experimental Medicine, Linköping University , Linköping, Sweden Find this author on Google Scholar Find this author on PubMed Search for this author on this site Maria Ling Lundström 8 Department of Medical Sciences, Gastroenterology Research Group, Uppsala University , Uppsala, Sweden Find this author on Google Scholar Find this author on PubMed Search for this author on this site Jóhann P Hreinsson 9 Department of Molecular and Clinical Medicine, Sahlgrenska Academy, University of Gothenburg , Göteborg, Sweden Find this author on Google Scholar Find this author on PubMed Search for this author on this site Sven Almer 4 Centre for Digestive Health, Department of Gastroenterology, Dermatovenereology and Rheumatology, Karolinska University Hospital , Stockholm, Sweden 10 Department of Medicine Solna, Karolinska Institutet , Stockholm, Sweden Find this author on Google Scholar Find this author on PubMed Search for this author on this site Francesca Bresso 4 Centre for Digestive Health, Department of Gastroenterology, Dermatovenereology and Rheumatology, Karolinska University Hospital , Stockholm, Sweden 10 Department of Medicine Solna, Karolinska Institutet , Stockholm, Sweden Find this author on Google Scholar Find this author on PubMed Search for this author on this site Carl Eriksson 3 Department of Gastroenterology, Faculty of Medicine and Health, Örebro University , Örebro, Sweden Find this author on Google Scholar Find this author on PubMed Search for this author on this site Olof Grip 11 Department of Gastroenterology, Skåne University Hospital , Malmö/Lund, Sweden Find this author on Google Scholar Find this author on PubMed Search for this author on this site André Blomberg 12 Department of Medicine, Geriatrics and Emergency Medicine, Sahlgrenska University Hospital, Östra Hospital , Gothenburg Find this author on Google Scholar Find this author on PubMed Search for this author on this site Jan Marsal 11 Department of Gastroenterology, Skåne University Hospital , Malmö/Lund, Sweden Find this author on Google Scholar Find this author on PubMed Search for this author on this site Niloofar Nikaein 1 School of Medical Sciences, Faculty of Medicine and Health, Örebro University , Örebro, Sweden Find this author on Google Scholar Find this author on PubMed Search for this author on this site Shoaib Bakhtyar 1 School of Medical Sciences, Faculty of Medicine and Health, Örebro University , Örebro, Sweden Find this author on Google Scholar Find this author on PubMed Search for this author on this site Carl Mårten Lindqvist 1 School of Medical Sciences, Faculty of Medicine and Health, Örebro University , Örebro, Sweden Find this author on Google Scholar Find this author on PubMed Search for this author on this site Elisabet Hultgren Hörnquist 1 School of Medical Sciences, Faculty of Medicine and Health, Örebro University , Örebro, Sweden Find this author on Google Scholar Find this author on PubMed Search for this author on this site Maria K Magnusson 13 Department of Microbiology and Immunology, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg , Sweden Find this author on Google Scholar Find this author on PubMed Search for this author on this site Åsa V Keita 14 Department of Biomedical and Clinical Sciences, Linköping University , Linköping, Sweden Find this author on Google Scholar Find this author on PubMed Search for this author on this site Mauro D’Amato 15 Gastrointestinal Genetics Lab, CIC bioGUNE - BRTA , Derio, Spain 16 Ikerbasque, Basque Foundation for Science , Bilbao, Spain 17 Department of Medicine and Surgery, LUM University , Casamassima, Italy Find this author on Google Scholar Find this author on PubMed Search for this author on this site Dirk Repsilber 1 School of Medical Sciences, Faculty of Medicine and Health, Örebro University , Örebro, Sweden Find this author on Google Scholar Find this author on PubMed Search for this author on this site Lena Öhman 13 Department of Microbiology and Immunology, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg , Sweden Find this author on Google Scholar Find this author on PubMed Search for this author on this site Johan D Söderholm 14 Department of Biomedical and Clinical Sciences, Linköping University , Linköping, Sweden 18 Department of Surgery, Linköping University , Linköping, Sweden Find this author on Google Scholar Find this author on PubMed Search for this author on this site Marie Carlson 8 Department of Medical Sciences, Gastroenterology Research Group, Uppsala University , Uppsala, Sweden Find this author on Google Scholar Find this author on PubMed Search for this author on this site Charlotte R H Hedin 4 Centre for Digestive Health, Department of Gastroenterology, Dermatovenereology and Rheumatology, Karolinska University Hospital , Stockholm, Sweden 10 Department of Medicine Solna, Karolinska Institutet , Stockholm, Sweden Find this author on Google Scholar Find this author on PubMed Search for this author on this site Robert Kruse 1 School of Medical Sciences, Faculty of Medicine and Health, Örebro University , Örebro, Sweden 19 Inflammatory Response and Infection Susceptibility Centre , (iRiSC), Faculty of Medicine and Health, Örebro University , Örebro, Sweden 20 Department of Clinical Research Laboratory, Faculty of Medicine and Health, Örebro University , Örebro, Sweden Find this author on Google Scholar Find this author on PubMed Search for this author on this site Jonas Halfvarson 3 Department of Gastroenterology, Faculty of Medicine and Health, Örebro University , Örebro, Sweden Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Jonas Halfvarson For correspondence: jonas.halfvarsson{at}regionorebrolan.se Abstract Full Text Info/History Metrics Data/Code Preview PDF Abstract Purpose There is a need for diagnostic and prognostic biosignatures to improve long-term outcomes in inflammatory bowel disease (IBD). Here, we describe the establishment of the Swedish inception cohort in IBD (SIC-IBD) and demonstrate its potential for the identification of such signatures. Participants Patients aged ≥18 years with gastrointestinal symptoms who were referred to the gastroenterology unit due to suspected IBD at eight Swedish hospitals between November 2011 and March 2021 were eligible for inclusion. Findings to date In total, 368 patients with IBD (Crohn’s disease, n=143; ulcerative colitis, n=201; IBD-unclassified, n=24) and 168 symptomatic controls were included. In addition, 59 healthy controls without gastrointestinal symptoms were recruited as a second control group. Biospecimens and clinical data were collected at inclusion and in patients with IBD also during follow-up to 10 years. Levels of faecal calprotectin and high-sensitivity C-reactive protein were higher in patients with IBD compared to symptomatic controls and healthy controls. Preliminary results highlight the potential of serum protein signatures and autoantibodies, as well as results from faecal markers, to differentiate between IBD and symptomatic controls in the cohort. During the first year of follow-up, 36% (52/143) of the patients with Crohn’s disease, 24% (49/201) with ulcerative colitis and 4% (1/24) with IBD-U experienced an aggressive disease course. Future plans We have established an inception cohort enabling ongoing initiatives to collect and generate clinical data and multi-omics datasets. The cohort will allow analyses for translation into candidate biosignatures to support clinical decision-making in IBD. Additionally, the data will provide insights into mechanisms of disease pathogenesis. Bullet points on strengths and weaknesses This large, multicentre inception cohort of newly diagnosed adult IBD patients, with integrated biobanking and prospective material collection, enables exploration of IBD pathophysiology and biomarker discovery. The inclusion of symptomatic controls with gastrointestinal symptoms mimicking IBD but without evidence of the diagnosis provides a realistic diagnostic setting and addresses limitations of many previous cohorts. The use of healthy controls as a second control group offers opportunities to gain insight into IBD pathogenesis. The non-population-based study design and the predominance of university hospitals in recruitment may limit the generalisability of findings. Suboptimal sample processing at some centres, including delays in serum centrifugation and transportation of faecal samples at ambient temperatures, may have affected the quality of some specific analyses, such as microbiota analyses. INTRODUCTION Inflammatory bowel disease (IBD), comprising Crohn’s disease, ulcerative colitis and IBD-unclassified (IBD-U), is a chronic disease that predominantly presents during the second and third decades of life. The disease results in an impaired quality of life for patients and substantial societal costs due to sick leave and a high use of healthcare resources [ 1 – 3 ]. Progressive inflammation causes damage to the gastrointestinal tract, and a substantial proportion of patients develop serious disease complications, including bowel obstruction, fistula, abscesses, and colorectal cancer [ 4 – 6 ]. IBD often presents with non-specific symptoms such as diarrhoea, fatigue and abdominal pain and, therefore, presents a diagnostic challenge. Commonly used biomarkers in diagnostic algorithms include C-reactive protein (CRP) and, in some regions, faecal calprotectin (FCP) which help identify patients needing referral for further investigations, including ileocolonoscopy [ 7 ]. However, the diagnostic accuracy of CRP is too low for reliably identifying IBD patients, and the utility of FCP is hampered by poor patient adherence to faecal sampling [ 8 , 9 ]. Furthermore, many healthcare systems do not reimburse the use of FCP for diagnostic purposes. The absence of reliable, non-invasive diagnostic biomarkers, occurrence of non-specific symptoms and limited access to ileocolonoscopy, frequently results in a significant diagnostic delay [ 10 , 11 ]. As a consequence, many patients have acquired considerable bowel damage (e.g., fistulas, strictures) already at diagnosis [ 4 , 11 ]. At diagnosis, the heterogeneity in clinical presentation and subsequent disease course make clinicians’ attempts to stratify the treatment according to the individual patient’s needs very difficult. While some patients experience an indolent disease course with minimal symptoms and low endoscopic activity, a substantial proportion exhibit an aggressive disease phenotype characterised by treatment refractoriness, corticosteroid dependency, frequent hospital admissions and surgical interventions, including resection surgery and acute colectomy [ 12 – 18 ]. For this latter group, an early effective treatment seems advantageous, as the initial disease phase may provide a “window of opportunity” where prompt suppression of intestinal inflammation could improve long-term outcomes [ 19 – 21 ]. Identifying prognostic biomarkers for this group of patients is therefore critical to facilitate the timely initiation of potent treatment. To address the need for both diagnostic and prognostic biomarkers, we established the “Swedish Inception Cohort in IBD” (SIC-IBD), a large prospective multicentre cohort involving patients with suspected IBD referred to eight hospitals in Sweden. After a comprehensive diagnostic work-up, patients were classified as incident IBD patients or symptomatic non-IBD controls, i.e., patients presenting with symptoms mimicking IBD but where IBD was ruled out. Alternative diagnoses in this patient group included infectious colitis, irritable bowel syndrome and diverticulitis. As a second control group, healthy controls without gastrointestinal symptoms were recruited. This cohort provides a rich collection of biospecimens together with detailed phenotypic characterisation collected both at diagnosis and during follow-up. Herein, we present the study design and baseline characteristics of the participants in the SIC-IBD. COHORT DESCRIPTION Inclusion This longitudinal multicentre cohort study was conducted across eight Swedish hospitals: Ersta Hospital, Karolinska University Hospital, Linköping University Hospital, Sahlgrenska University Hospital, Skåne University Hospital, Södra Älvsborg Hospital, Uppsala University Hospital, and Örebro University Hospital. Patients aged ≥18 years with gastrointestinal symptoms, such as diarrhoea, abdominal pain and blood or mucus in stools, who were referred to the gastroenterology unit with suspected IBD between November 2011 and March 2021 were eligible for inclusion ( Figure 1 ). Exclusion criteria included a previous diagnosis of Crohn’s disease, ulcerative colitis or IBD unclassified, or inability to provide informed consent or to comply with protocol requirements. After obtaining written informed consent, all patients underwent a routine diagnostic work-up for IBD, following clinical practice and international guidelines [ 22 ]. Download figure Open in new tab Figure 1. The flow diagram shows the number of included individuals at each hospital, the number of patients excluded and the final number of patients and controls in the Swedish Inception Cohort in inflammatory bowel disease (SIC-IBD). Based on the diagnostic work-up, which included magnetic resonance imaging in cases where small bowel involvement was suspected, patients were classified as having incident IBD or as symptomatic controls, i.e., patients with no discernible evidence of IBD at inclusion or during follow-up. The diagnosis of IBD was based on internationally accepted clinical, endoscopic, radiological, and histological criteria [ 22 ]. Nine patients were excluded due to suspected or confirmed IBD during follow-up. Patients were followed prospectively according to clinical practice, with data collected after 3 months, 1, 3, 5, 7 and 10 years for those with IBD. In addition, a group of healthy controls, without gastrointestinal disease, was included at baseline. Demographics of patients and controls During the inclusion period, 368 patients with IBD (Crohn’s disease, n=143; ulcerative colitis, n=201; IBD-U, n=24) and 168 symptomatic controls were included ( Table 1 ). The group of symptomatic controls comprised patients who ultimately were diagnosed with various diseases, including microscopic colitis, infectious enteritis, celiac disease, or irritable bowel syndrome. In addition, 59 healthy controls without any history of gastrointestinal disease were recruited as a second control group. View this table: View inline View popup Download powerpoint Table 1. Demographics of individuals included in the Swedish Inception Cohort in IBD (SIC-IBD). Healthcare setting Sweden has a tax-funded universal healthcare system, and private outpatient healthcare providers are few within the field of gastroenterology. In general, gastroenterologists at secondary or tertiary care centres (rather than primary care) are responsible for diagnosing and managing patients with IBD. Data collection Characterisation of disease phenotype and disease activity Following informed consent, data on patient demographics, disease phenotype according to the Montreal classification[ 23 ], extraintestinal manifestations, endoscopic activity (defined as the presence of ulcers in Crohn’s disease [yes/no] and the Mayo endoscopic subscore in ulcerative colitis), IBD treatment, IBD-related surgery, and hospital admission were recorded at baseline and prospectively during follow-up. Treatment-naivety was defined as no prior treatment with IBD-related medications, including topical therapies. Previous treatments in patients who were not treatment-naïve included mostly topical therapies but also a few days of corticosteroid treatment. For healthy controls, information about basic demographics was collected. Data on disease characteristics were recorded using case report forms (CRFs), and details on the Montreal classification and clinical disease activity at baseline are provided in Table 2 . View this table: View inline View popup Download powerpoint Table 2. Clinical characteristics of patients with Crohn’s disease, ulcerative colitis and IBD-unclassified in the Swedish Inception Cohort in IBD (SIC-IBD). Patient-reported outcomes Patient questionnaires were employed to obtain information about clinical disease activity, smoking status, recent antibiotic or non-steroid anti-inflammatory drug use, and any specific dietary restrictions. Patients were also asked to complete the Short-Health-Scale and Short Form-36 (SF-36) questionnaire to obtain information about Health-Related Quality of Life (HRQoL) [ 24 – 26 ]. SF-36 is a general measure of HRQoL, whereas the Short-Health Scale is a validated measure to address HRQoL in patients with IBD. It includes four dimensions: bowel symptoms, daily life activities, worry and general well-being. Additional quality of life data were collected using the EuroQol-5D (EQ-5D) questionnaire[ 27 , 28 ]. Mental health was evaluated using the Patient-health Questionnaire 9 (PHQ9) [ 29 ], the Cognitive Reserve Index (CRI) [ 30 ], and the Short-Form Health Survey (SF-36) [ 26 ]. Additional data on gastrointestinal symptoms was obtained by using the Gastrointestinal Symptom Rating Scale (GSRS) [ 31 ] and the Rome III criteria functional gastrointestinal disorders [ 32 ]. Sample collection and biobanking Biospecimens were obtained at baseline and during follow-up, processed and biobanked according to predefined standard operating procedures (SOPs). Blood samples were collected in EDTA and PAX®-tubes. In addition, serum samples were obtained by centrifugation of whole blood at 2400 × g for 5 min at ambient temperature, followed by aliquoting of serum and storing at −80° C. For six centres, blood samples were shipped unprocessed at ambient room temperature and centrifuged upon arrival at the central biobank, Örebro, Sweden. The participants collected faecal samples in plastic tubes at home, brought them to the hospital or mailed them by postal service. On arrival, the samples were immediately frozen and stored at −80°C. Spot urine samples were collected during study visits, aliquoted and stored at −80°C. In addition to collecting biopsies as part of clinical routine, physicians were instructed to take intestinal biopsies from both inflamed and non-inflamed mucosa according to a predefined protocol. These biopsies were preserved in Allprotect Tissue Reagent (Qiagen, Hilden, Germany) and in a bacterial freezing medium. Biopsies in the freezing medium were immediately stored at −80°C, whereas those in Allprotect Tissue Reagent were handled according to the manufacturer’s instructions. Details on the collected biological material are provided in Table 3 . View this table: View inline View popup Download powerpoint Table 3. An overview of biospecimens collected at baseline from individuals within the Swedish Inception Cohort in inflammatory bowel disease (SIC-IBD). Measurements of high-sensitivity CRP and faecal c alprotectin After storage, samples for high-sensitivity (hs) CRP (serum) and calprotectin (faeces) were retrieved from the central biobank and sent to Uppsala Clinical Research Center, Uppsala, Sweden and Academic Laboratory, Department of Clinical Chemistry, University Hospital, Uppsala, Sweden, respectively. hsCRP was assayed in a single batch for all participants at the end of the recruitment period, using a particle-enhanced immunoturbidimetric hsCRP assay (Cardiac C-Reactive Protein (Latex) High Sensitive, Roche Diagnostics) on a Roche Cobas c501. Correspondingly, faecal calprotectin was extracted and analysed according to the manufacturer’s instructions, with a chemiluminescent immunoassay, using the LIASON XL analyser (DiaSorin, Saluggia, Italy). Data on median levels of hsCRP and FCP across the various diagnoses are provided in Table 1 . Disease course outcome during follow-up A composite outcome measure was used to categorise the disease course as aggressive or indolent during follow-up. An aggressive disease course was defined as the presence of any IBD-related surgery, hospital admission for active disease, treatment refractoriness towards targeted therapies, i.e., biologics, Janus kinase (JAK) inhibitors or sphingosine-1-phosphate receptor modulators, and >two courses or high cumulative dosis of systemic corticosteroids within the first year of follow-up ( Table 4 ). In addition, Crohn’s disease patients with evidence of progression to a complicated disease behaviour, i.e., a new stricture, fistula, or abscess, were also categorised as having an aggressive disease course. View this table: View inline View popup Download powerpoint Table 4. Criteria for defining the disease course as aggressive or indolent within the Swedish Inception Cohort in inflammatory bowel disease (SIC-IBD). Patients with any of the following events during the first year from the date of diagnosis were defined as having an aggressive disease course. Data management Patients, physicians, or research nurses used CRFs and predefined questionnaires to collect information. All data were imported after pseudonymisation into a central database with reading access for all co-investigators. The database is updated every 6-12 months to allow the import of new data, including follow-up visits, address possible missing information, and correct potential erroneous data entries. To enable backward traceability, a data freeze is created at each update. Each data freeze provides a snapshot of information contained in the database at a given date. Project organisation The SIC-IBD represents a crucial element of the multi-modal national study to identify biomarkers for diagnosis, therapy response and disease progression in IBD (BIO IBD), which aims to bring leading clinicians, clinical researchers and basic scientists within the field of IBD together with corporate partners. The managerial structure and the operational organisation of BIO IBD are shown in Figure 2 . An executive office has been set up at the Faculty of Health and Medical Sciences, Örebro University, forming the BIO IBD Executive Committee together with representatives of participating universities and university hospitals. The Executive Committee coordinated the efforts of the work packages, clinical departments, biomedical companies, and the Swedish patients’ organisation, Mag -och tarmförbundet [ 33 ]. Download figure Open in new tab Figure 2. Managerial structure and the operational organisation of the multi-modal national study to identify biomarkers for diagnosis, therapy response and disease progression in inflammatory bowel disease (BIO IBD), where the Swedish inception cohort in IBD (SIC-IBD) represents an important resource. The Steering Committee, responsible for the strategic leadership, is formed by representatives from involved universities, biomedical companies and the patient organisation, with equal numbers of basic scientists and clinicians, equal gender, and representation of young scientists. The Advisory Board, composed of internationally renowned representatives of academia and the biomedical industry, provides external review and input. Patient and Public Involvement statement During the planning phase of the cohort study, patient representatives from the Swedish patient’s organisation, Mag-och tarmförbundet provided input on the study design, including the definition of the disease course during follow-up. Also, they assessed the burden of the collection of biological material and the time required for responding to the questionnaires in the study. Representatives of the patient organisation and the Swedish biomarker manufacturers in the executive committee also provided feedback during the recruitment process and follow-up of study participants. In addition to scientific reporting, key findings of the studies will be communicated to patient organisations, public health policymakers, and the public through various media and news activities. When disseminating the results, the recommendations of the International Committee of Medical Journal Editors (ICMJE)will be applied [ 34 ]. FINDINGS TO DATE At baseline, differences in smoking habits were observed between patients with Crohn’s disease, ulcerative colitis, and IBD-U. Active smoking was more prevalent in patients with Crohn’s disease, while a higher rate of former smokers was found in patients with ulcerative colitis. While hsCRP measurements were available for 90% of all patients and controls, only 63% of patients and controls had available FCP measures in the study. An additional 44 measurements of FCP at diagnosis were available from clinical routine, but these results were excluded from this analysis due to the use of different assays. Both FCP and hsCRP levels were higher in patients with Crohn’s disease and ulcerative colitis compared to symptomatic controls and healthy controls. However, while FCP levels were significantly elevated in IBD unclassified compared to symptomatic controls, the difference in hsCRP levels between these two groups was not statistically significant. No significant differences in FCP levels were observed between patients with Crohn’s disease and ulcerative colitis, but hsCRP levels were higher in Crohn’s disease patients. Significant differences in hsCRP and FCP levels were also found between symptomatic controls and healthy controls. Preliminary results from analyses of serum proteins as well as findings from the analyses of faecal markers have highlighted the potential of these markers to differentiate between patients with IBD and symptomatic controls in this cohort, suggesting their diagnostic value [ 35 , 36 ]. Recent results from the analysis of anti-αvβ6 autoantibodies further suggested a high diagnostic value for ulcerative colitis of this marker [ 37 ]. Additionally, preliminary data indicate differences in mucosal proteins between patients developing an aggressive course of ulcerative colitis and those with an indolent course [ 38 ]. In line with previous studies [ 19 , 39 ], we employed a composite outcome to characterise the disease course within the first year after diagnosis, either as aggressive or indolent ( Table 4 ). An aggressive course was defined by treatment refractoriness, the need for surgical resection, or in the case of Crohn’s disease, the development of severe complications such as strictures and fistulas. Based on this definition, 36% (52/143) of the patients with Crohn’s disease, 24% (49/201) of those with ulcerative colitis, and 4.2% (1/24) with IBD-U experienced an aggressive disease course within the first year after diagnosis ( Supplementary Table 1 ). These results underscore that treatment failure rates and disease complications remain unacceptably high in IBD. Aggressive disease course was associated with more extensive ulcerative colitis, while no association was found between Crohn’s disease location and disease course. View this table: View inline View popup Download powerpoint Supplementary Table 1 STRENGTHS AND LIMITATIONS In this large nationwide multicentre inception cohort of newly diagnosed patients with IBD, a set of highly relevant biospecimens were collected at inclusion, and patients were prospectively followed. This cohort can be used to gain insights into key pathogenic mechanisms of IBD. Moreover, it provides a valuable resource for biomarker discoveries, particularly the identification of diagnostic biomarkers for IBD and prognostic markers for future disease courses. This cohort is one of few large-scale IBD inception cohorts of adult patients with integrated biobanking [ 40 – 42 ], as most of the earlier initiatives have included paediatric patients only. Most previous attempts to identify diagnostic biomarkers in inception cohorts have used healthy controls or patients with non-inflammatory conditions (e.g., irritable bowel syndrome) as a control group. These settings do not reflect a diagnostic scenario where patients with gastrointestinal symptoms that are indicative of IBD are examined. Accordingly, evaluations based on these cohorts are likely to overestimate the diagnostic capacity of potential biomarkers [ 43 ]. However, this limitation is rarely acknowledged and may partly explain why promising biomarkers fail in replication attempts and do not make their way to the clinic. To allow the identification of diagnostic biomarkers, we have included patients with symptoms indicative of IBD but without any signs of the disease at diagnostic work-up or during follow-up (symptomatic controls) as a reference group. Thus, both cases with IBD and symptomatic controls represented an unselected sample of patients who were referred to secondary care for the suspicion of IBD. In addition, we included healthy controls as a second control group to gain insight into the aetiology of IBD and to characterise pathways related to disease pathogenesis. In this cohort, we did not record the number of eligible patients who were not included, e.g. those who declined to or were not able to give informed consent or were not identified by study personnel. The absence of a population-based cohort design could be a limiting factor when interpreting associations between exposures and clinical outcomes within SIC-IBD. However, the proportion of IBD patients with Crohn’s disease in this study (39%), the European Crohn’s and Colitis Organization’s Epidemiological Committee (EpiCom) inception cohort (37%) and the recent population-based Inflammatory bowel disease in South-Eastern Norway cohort III (35%) were similar. Likewise, the proportions of ulcerative colitis (54%, 52% and 61%) and IBD-U (7%, 11% and 4%) were similar in the three cohorts. Suboptimal procedures in sample collection further limited the study. To enable inclusion at all centres, serum samples collected at centres with limited sample processing capacity were shipped overnight to a central biobank for centrifugation and biobanking. While measured faecal markers such as calprotectin are stable at room temperature for several days, microbiome analyses are sensitive to pre-analytic sample handling [ 44 – 46 ]. COLLABORATION We have established an inception cohort of newly diagnosed adult patients with IBD, symptomatic controls and healthy controls with integrated biobanking. Initiatives are underway to generate various multi–omics data from samples collected at baseline and follow-up visits. Analyses of single and multiple datasets, including integration of clinical variables, may discover novel diagnostic and prognostic biosignatures for IBD and its subtypes. Comparisons with healthy controls may also provide insights into IBD pathogenesis and progression mechanisms. We encourage collaborations with researchers from other cohorts and case-control studies to validate findings from the SIC-IBD cohort. Also, researchers can propose new collaborative initiatives and apply for access to data and biospecimens by submitting a proposal to the BIO IBD Executive Office ( BIO.IBD{at}oru.se ). All proposals will be reviewed on scientific quality and methodology by the BIOIBD executive committee. Data Availability Researchers can apply for access to data and biological specimens by submitting a proposal to the BIO IBD Executive Office ( BIO.IBD{at}oru.se ), including a copy of their ethics approval. All proposals will be reviewed by the BIO IBD executive committee based on scientific quality and methodology. This procedure is installed to ensure that the clinical data and biological material are being requested for scientific purposes, in accordance with the informed consent signed by the participants, as the collected data and material cannot be used by purely commercial parties. Additionally, any transfer of data or biological material must comply with Swedish law and the European Union (EU) General Data Protection Regulation (GDPR). Authors’ contributions Conception and design : Jonas Halfvarson Drafting the manuscript : Benita Salomon, Olle Grännö and Jonas Halfvarson Critical revision for intellectual content : All authors Final approval : All authors Accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved : All authors Competing interests statement DB served as a speaker and/or advisory board member for BMS, Janssen, Pfizer, Pharmacosmos, Sandoz, Takeda and Tillotts Pharma. HS has served as speaker and/or advisory board member for AbbVie Ferring, Janssen, Pfizer, Takeda, Gilead and Tillotts Pharma. AC served as a speaker for Takeda and Ferring. HH has served as a speaker, consultant or advisory board member for AbbVie, Ferring, Fresenius Kabi, Janssen, Norgine, Pfizer, Pharmacosmos, Takeda and Tillotts and has received grant support from AbbVie, Ferring, Takeda, and Tillotts. SA served as a member for Scientific committee/Advisory board of, Janssen, Pharmacosmos, Takeda, as a consultant for Janssen, OrionPharm, Takeda, and as a speaker: Galapagos, Janssen, Tillotts, received research grants from Janssen and OrionPharma. FB has acted as national and/or local principal investigator for clinical trials for Janssen, Ferring and Abbvie. CE received grant support/lecture fee/advisory board from Takeda, Janssen Cilag, Pfizer, Abbvie. OG served as speaker and/or advisory board member for Abbvie, Bristol Mayer Squibb, Eli Lilly, Ferring, Janssen, Pfizer Takeda, Tillotts Pharma and Vifor Pharma. JM has served as a speaker, consultant or advisory board member for AbbVie, Alfasigma, Amgen, Bayer, Biogen, BMS, Eli Lilly, Ferring, Galapagos, Hospira, ITH, Janssen, Lument, MSD, Otsuka, Pfizer, Sandoz, Takeda, Tillotts and UCB; and has received grant support (not for this study) from AbbVie, BMS, Calpro AS, Carbiotix, Ferring, Fresenius Kabi, Pfizer, Svar Life Science and Takeda. MKM has received speaker’s fees from Takeda and Janssen. LÖ has received a financial support for research by Genetic Analysis AS, Biocodex, Danone Research and AstraZeneca and served as Consultant/Advisory Board member for Genetic Analysis AS, and as a speaker for Biocodex, Ferring Pharmaceuticals, Takeda, AbbVie, Novartis, Janssen-Cilag and Meda. MC has received speaker’s fees from ViforPharma. She is the national PI for clinical trials for AstraZeneca. CRHH has served as a speaker and/or advisory board member for AstraZeneca, Dr Falk Pharma and the Falk Foundation, Galapagos, Janssen, Pfizer, Takeda, Tillotts Pharma, and received grant support from Tillotts and Takeda. JH served as speaker and/or advisory board member from AbbVie, Alfasigma, Aqilion, Bristol Myers Squibb, Celgene, Celltrion, Dr Falk Pharma and the Falk Foundation, Eli Lilly, Ferring, Galapagos, Gilead, Hospira, Index Pharma, Janssen, MEDA, Medivir, Medtronic, Merck, MSD, Novartis, Pfizer, Prometheus Laboratories Inc., Sandoz, Shire, STADA, Takeda, Thermo Fisher Scientific, Tillotts Pharma, Vifor Pharma, UCB and received grant support from Janssen, MSD and Takeda. The remaining authors declare no conflicts of interest. Funding This work was supported by the Swedish Foundation for Strategic Research [RB13-0160 to J.H.], the Swedish Research Council [2020-02021 to J.H.], and the Örebro University Hospital research foundation [OLL-962042, OLL-974710, OLL-986849, OLL-1001470 to J.H.]. The funding sponsors had no role in the study’s design; collection, management, analysis, or interpretation of data; in writing of the protocol, or the decision to submit results for publication. Ethical approval The SIC-IBD study was approved by the Regional Ethics Committees (Dnr 2010/313). Written informed consent was obtained from all participants before inclusion. Provenance and peer review Not commissioned; externally peer-reviewed. Data sharing statement Researchers can apply for access to data and biological specimens by submitting a proposal to the BIO IBD Executive Office ( BIO.IBD{at}oru.se ), including a copy of their ethics approval. All proposals will be reviewed by the BIOIBD executive committee based on scientific quality and methodology. This procedure is installed to ensure that the clinical data and biological material are being requested for scientific purposes, in accordance with the informed consent signed by the participants, as the collected data and material cannot be used by purely commercial parties. Additionally, any transfer of data or biological material must comply with Swedish law and the European Union (EU) General Data Protection Regulation (GDPR). Acknowledgements The authors would like to thank the SIC-IBD participants, involved nurses and physicians at the SIC-IBD study sites for their contribution. Also, the authors thank Åsa Smedberg and Anette Oskarsson for administrative support. References ↵ Lönnfors S , Vermeire S , Avedano L . IBD and health-related quality of life — Discovering the true impact . J Crohns Colitis . 2014 ; 8 : 1281 – 6 . doi: 10.1016/j.crohns.2014.03.005 OpenUrl CrossRef PubMed Park KT , Ehrlich OG , Allen JI , et al. The Cost of Inflammatory Bowel Disease: An Initiative From the Crohn’s & Colitis Foundation . Inflamm Bowel Dis . 2020 ; 26 : 1 – 10 . doi: 10.1093/ibd/izz104 OpenUrl CrossRef PubMed ↵ Khalili H , Everhov ÅH , Halfvarson J , et al. Healthcare use, work loss and total costs in incident and prevalent Crohn’s disease and ulcerative colitis: results from a nationwide study in Sweden . Aliment Pharmacol Ther . 2020 ; 52 : 655 – 68 . doi: 10.1111/apt.15889 OpenUrl CrossRef PubMed ↵ Peyrin-Biroulet L , Loftus EVJ , Colombel J-F , et al. The Natural History of Adult Crohn’s Disease in Population-Based Cohorts . Am J Gastroenterol . 2010 ; 105 : 289 – 97 . doi: 10.1038/ajg.2009.579 OpenUrl CrossRef PubMed Jess T , Rungoe C , Peyrin–Biroulet L. Risk of Colorectal Cancer in Patients With Ulcerative Colitis: A Meta-analysis of Population-Based Cohort Studies . Clin Gastroenterol and Hepatol . 2012 ; 10 : 639 – 45 . doi: 10.1016/j.cgh.2012.01.010 OpenUrl CrossRef PubMed ↵ Torres J , Billioud V , Sachar DB , et al. Ulcerative Colitis as A Progressive Disease: The Forgotten Evidence . Inflamm Bowel Dis . 2012 ; 18 : 1356 – 63 . doi: 10.1002/ibd.22839 OpenUrl CrossRef PubMed Web of Science ↵ Brookes MJ , Whitehead S , Gaya DR , et al. Practical guidance on the use of faecal calprotectin . Frontline Gastroenterol . 2018 ; 9 : 87 – 91 . doi: 10.1136/flgastro-2016-100762 OpenUrl Abstract / FREE Full Text ↵ Maréchal C , Aimone-Gastin I , Baumann C , et al. Compliance with the faecal calprotectin test in patients with inflammatory bowel disease . United European Gastroenterol J . 2017 ; 5 : 702 – 7 . doi: 10.1177/2050640616686517 OpenUrl CrossRef PubMed ↵ Khakoo NS , Lewis A , Roldan GA , et al. Patient Adherence to Fecal Calprotectin Testing Is Low Compared to Other Commonly Ordered Tests in Patients With Inflammatory Bowel Disease . Crohns Colitis 360 . 2021 ; 3 : otab028 . doi: 10.1093/crocol/otab028 OpenUrl CrossRef ↵ Burisch J , Ungaro R , Vind I , et al. Proximal Disease Extension in Patients With Limited Ulcerative Colitis: A Danish Population-based Inception Cohort . J Crohns Colitis . 2017 ; 11 : 1200 – 4 . doi: 10.1093/ecco-jcc/jjx066 OpenUrl CrossRef PubMed ↵ Schoepfer AM , Dehlavi M-A , Fournier N , et al. Diagnostic Delay in Crohn’s Disease Is Associated With a Complicated Disease Course and Increased Operation Rate . Am J Gastroenterol . 2013 ; 108 : 1744 – 53 . doi: 10.1038/ajg.2013.248 OpenUrl CrossRef PubMed ↵ Solberg IC , Lygren I , Jahnsen J , et al. Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study) . Scand J Gastroenterol . 2009 ; 44 : 431 – 40 . doi: 10.1080/00365520802600961 OpenUrl CrossRef PubMed Web of Science Solberg IC , Vatn MH , Høie O , et al. Clinical Course in Crohn’s Disease: Results of a Norwegian Population-Based Ten-Year Follow-Up Study . Clin Gastroenterol Hepatol . 2007 ; 5 : 1430 – 8 . doi: 10.1016/j.cgh.2007.09.002 OpenUrl CrossRef PubMed Web of Science Burisch J , Pedersen N , Cukovic-Cavka S , et al. Initial Disease Course and Treatment in an Inflammatory Bowel Disease Inception Cohort in Europe: The ECCO-EpiCom Cohort . Inflamm Bowel Dis . 2014 ; 20 : 36 – 46 . doi: 10.1097/01.MIB.0000436277.13917.c4 OpenUrl CrossRef PubMed Web of Science Burisch J , Katsanos KH , Christodoulou DK , et al. Natural Disease Course of Ulcerative Colitis During the First Five Years of Follow-up in a European Population-based Inception Cohort—An Epi-IBD Study . J Crohns Colitis . 2019 ; 13 : 198 – 208 . doi: 10.1093/ecco-jcc/jjy154 OpenUrl CrossRef PubMed Burisch J , Kiudelis G , Kupcinskas L , et al. Natural disease course of Crohn’s disease during the first 5 years after diagnosis in a European population-based inception cohort: an Epi-IBD study . Gut . 2019 ; 68 : 423 – 33 . doi: 10.1136/gutjnl-2017-315568 OpenUrl Abstract / FREE Full Text Zhulina Y , Udumyan R , Tysk C , et al. The changing face of Crohn’s disease: a population-based study of the natural history of Crohn’s disease in Örebro, Sweden 1963–2005 . Scand J Gastroenterol . 2016 ; 51 : 304 – 13 . doi: 10.3109/00365521.2015.1093167 OpenUrl CrossRef PubMed ↵ Everhov ÅH , Halfvarson J , Myrelid P , et al. Incidence and Treatment of Patients Diagnosed With Inflammatory Bowel Diseases at 60 Years or Older in Sweden . Gastroenterology . 2018 ; 154 : 518 – 528.e15 . doi: 10.1053/j.gastro.2017.10.034 OpenUrl CrossRef PubMed ↵ Khanna R , Bressler B , Levesque BG , et al. Early combined immunosuppression for the management of Crohn’s disease (REACT): a cluster randomised controlled trial . Lancet . 2015 ; 386 : 1825 – 34 . doi: 10.1016/S0140-6736(15)00068-9 OpenUrl CrossRef PubMed Colombel J-F , Panaccione R , Bossuyt P , et al. Effect of tight control management on Crohn’s disease (CALM): a multicentre, randomised, controlled phase 3 trial . The Lancet . 2017 ; 390 : 2779 – 89 . doi: 10.1016/S0140-6736(17)32641-7 OpenUrl CrossRef PubMed ↵ Satsangi J , Nowak J , Kalla R , et al. Treatment strategies and biomarkers in Crohn’s disease: the PROFILE trial . Lancet Gastroenterol Hepatol . 2024 ; 9 : 591 – 2 . doi: 10.1016/S2468-1253(24)00082-7 OpenUrl CrossRef ↵ Maaser C , Sturm A , Vavricka SR , et al. ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications . J Crohns Colitis . 2019 ; 13 : 144 – 164K . doi: 10.1093/ecco-jcc/jjy113 OpenUrl CrossRef PubMed ↵ Silverberg MS , Satsangi J , Ahmad T , et al. Toward an Integrated Clinical, Molecular and Serological Classification of Inflammatory Bowel Disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology . Can J Gastroenterol . 2005 ; 19 : 5A - 36A . doi: 10.1155/2005/269076 OpenUrl CrossRef PubMed ↵ Hjortswang H , Järnerot G , Curman B , et al. The Short Health Scale: A valid measure of subjective health in ulcerative colitis . Scand J Gastroenterol . 2006 ; 41 : 1196 – 203 . doi: 10.1080/00365520600610618 OpenUrl CrossRef PubMed Stjernman H , Grännö C , Järnerot G , et al. Short health scale: A valid, reliable, and responsive instrument for subjective health assessment in Crohns disease: Inflamm Bowel Dis . 2008 ; 14 : 47 – 52 . doi: 10.1002/ibd.20255 OpenUrl CrossRef PubMed Web of Science ↵ Mchorney CA , Johne W , Anastasiae R . The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and Clinical Tests of Validity in Measuring Physical and Mental Health Constructs . Medical Care . 1993 ; 31 : 247 – 63 . doi: 10.1097/00005650-199303000-00006 OpenUrl CrossRef PubMed Web of Science ↵ EuroQol - a new facility for the measurement of health-related quality of life . Health Policy . 1990 ; 16 : 199 – 208 . doi: 10.1016/0168-8510(90)90421-9 OpenUrl CrossRef PubMed Web of Science ↵ Rabin R , Charro FD . EQ-SD: a measure of health status from the EuroQol Group . Annals of Medicine . 2001 ; 33 : 337 – 43 . doi: 10.3109/07853890109002087 OpenUrl CrossRef PubMed Web of Science ↵ Kroenke K , Spitzer RL . The PHQ-9: A New Depression Diagnostic and Severity Measure . Psychiatric Annals . 2002 ; 32 : 509 – 15 . doi: 10.3928/0048-5713-20020901-06 OpenUrl CrossRef PubMed Web of Science ↵ Nucci M , Mapelli D , Mondini S . Cognitive Reserve Index questionnaire (CRIq): a new instrument for measuring cognitive reserve . Aging Clin Exp Res . 2012 ; 24 : 218 – 26 . doi: 10.1007/BF03654795 OpenUrl CrossRef PubMed ↵ Svedlund J , Sjödin I , Dotevall G . GSRS - A clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer disease . Digest Dis Sci . 1988 ; 33 : 129 – 34 . doi: 10.1007/BF01535722 OpenUrl CrossRef PubMed Web of Science ↵ Drossman DA . The Functional Gastrointestinal Disorders and the Rome III Process . Gastroenterology . 2006 ; 130 : 1377 – 90 . doi: 10.1053/j.gastro.2006.03.008 OpenUrl CrossRef PubMed Web of Science ↵ Mag-och tarmförbundet . https://magotarm.se/ . Last Accessed 10 Jan 2025 . ↵ International Committee of Medical Journal Editors . Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly work in Medical Journals . Published Online First : 2024 . ↵ Bazov I , Kruse R , Bergemalm D , et al. P154 A novel serum protein signature as biomarker for Inflammatory Bowel Disease: A diagnostic performance and prediction modelling study using data from two independent inception cohorts . J Crohns Colitis . 2023 ; 17 : i314 – 5 . doi: 10.1093/ecco-jcc/jjac190.0284 OpenUrl CrossRef ↵ Ling Lundström M , Peterson C , Hedin CRH , et al. Faecal biomarkers for diagnosis and prediction of disease course in treatment naïve patients with IBD . Aliment Pharmacol Ther . 2024 ; 60 : 765 – 77 . doi: 10.1111/apt.18154 OpenUrl CrossRef PubMed ↵ Pertsinidou E , Salomon , B , Bergemalm D , et al. Anti-αvβ6 Integrin Autoantibodies associate with a distinct serum inflammatory profile at diagnosis of ulcerative colitis and define a severe phenotype of the disease . UEG Week 2024 Abstract Issue . Publisher: Elsevier 2024 . ↵ Salomon B , Carlson M , Bergemalm D , et al. P219 Prognostic potential of mucosal proteins in Ulcerative Colitis . J Crohns and Colitis . 2024 ; 18 : i549 – 50 . doi: 10.1093/ecco-jcc/jjad212.0349 OpenUrl CrossRef ↵ Jairath , Vipul R , Khanna R , Guizzetti L , et al. A cluster-randomised controlled trial of an enhanced treatment algorithm for the management of Crohn’s disease: REACT-2 . Lancet Gastroenterol Hepatol . 2022 ; 7 : 1080 . doi: 10.1016/S2468-1253(22)00357-0 OpenUrl CrossRef ↵ Gevers D , Kugathasan S , Denson LA , et al. The treatment-naive microbiome in new-onset Crohn’s disease . Cell Host Microbe . 2014 ; 15 : 382 – 92 . doi: 10.1016/j.chom.2014.02.005 OpenUrl CrossRef PubMed Web of Science Kristensen VA , Opheim R , Perminow G , et al. Inflammatory bowel disease in South-Eastern Norway III (IBSEN III): a new population-based inception cohort study from South-Eastern Norway . Scand J Gastroenterol . 2021 ; 56 : 899 – 905 . doi: 10.1080/00365521.2021.1922746 OpenUrl CrossRef PubMed ↵ Attauabi M , Madsen GR , Bendtsen F , et al. Influence of Genetics, Immunity and the Microbiome on the Prognosis of Inflammatory Bowel Disease (IBD Prognosis Study): the protocol for a Copenhagen IBD Inception Cohort Study . BMJ Open . 2022 ; 12 : e055779 . doi: 10.1136/bmjopen-2021-055779 OpenUrl Abstract / FREE Full Text ↵ Lijmer JG . Empirical Evidence of Design-Related Bias in Studies of Diagnostic Tests . JAMA . 1999 ; 282 : 1061 . doi: 10.1001/jama.282.11.1061 OpenUrl CrossRef PubMed Web of Science ↵ Carstens A , Roos A , Andreasson A , et al. Differential clustering of fecal and mucosa-associated microbiota in ‘healthy’ individuals . J Dig Dis . 2018 ; 19 : 745 – 52 . doi: 10.1111/1751-2980.12688 OpenUrl CrossRef PubMed RØseth AG , Fagerhol MK , Aadland E , et al. Assessment of the Neutrophil Dominating Protein Calprotectin in Feces: A Methodologic Study . Scand J Gastroenterol . 1992 ; 27 : 793 – 8 . doi: 10.3109/00365529209011186 OpenUrl CrossRef PubMed Web of Science ↵ Lasson A , Stotzer P-O , Öhman L , et al. The intra-individual variability of faecal calprotectin: A prospective study in patients with active ulcerative colitis . J Crohns Colitis . 2014 ; S1873994614001858 . doi: 10.1016/j.crohns.2014.06.002 OpenUrl CrossRef PubMed View the discussion thread. Back to top Previous Next Posted January 13, 2025. Download PDF Data/Code Email Thank you for your interest in spreading the word about medRxiv. NOTE: Your email address is requested solely to identify you as the sender of this article. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas. You are going to email the following Cohort profile: The Swedish Inception Cohort in inflammatory bowel disease (SIC-IBD) Message Subject (Your Name) has forwarded a page to you from medRxiv Message Body (Your Name) thought you would like to see this page from the medRxiv website. Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Share Cohort profile: The Swedish Inception Cohort in inflammatory bowel disease (SIC-IBD) Benita Salomon , Olle Grännö , Daniel Bergemalm , Hans Strid , Adam Carstens , Henrik Hjortswang , Maria Ling Lundström , Jóhann P Hreinsson , Sven Almer , Francesca Bresso , Carl Eriksson , Olof Grip , André Blomberg , Jan Marsal , Niloofar Nikaein , Shoaib Bakhtyar , Carl Mårten Lindqvist , Elisabet Hultgren Hörnquist , Maria K Magnusson , Åsa V Keita , Mauro D’Amato , Dirk Repsilber , Lena Öhman , Johan D Söderholm , Marie Carlson , Charlotte R H Hedin , Robert Kruse , Jonas Halfvarson medRxiv 2025.01.12.25320315; doi: https://doi.org/10.1101/2025.01.12.25320315 Share This Article: Copy Citation Tools Cohort profile: The Swedish Inception Cohort in inflammatory bowel disease (SIC-IBD) Benita Salomon , Olle Grännö , Daniel Bergemalm , Hans Strid , Adam Carstens , Henrik Hjortswang , Maria Ling Lundström , Jóhann P Hreinsson , Sven Almer , Francesca Bresso , Carl Eriksson , Olof Grip , André Blomberg , Jan Marsal , Niloofar Nikaein , Shoaib Bakhtyar , Carl Mårten Lindqvist , Elisabet Hultgren Hörnquist , Maria K Magnusson , Åsa V Keita , Mauro D’Amato , Dirk Repsilber , Lena Öhman , Johan D Söderholm , Marie Carlson , Charlotte R H Hedin , Robert Kruse , Jonas Halfvarson medRxiv 2025.01.12.25320315; doi: https://doi.org/10.1101/2025.01.12.25320315 Citation Manager Formats BibTeX Bookends EasyBib EndNote (tagged) EndNote 8 (xml) Medlars Mendeley Papers RefWorks Tagged Ref Manager RIS Zotero Tweet Widget Facebook Like Google Plus One Subject Area Gastroenterology Subject Areas All Articles Addiction Medicine (568) Allergy and Immunology (863) Anesthesia (299) Cardiovascular Medicine (4422) Dentistry and Oral Medicine (443) Dermatology (382) Emergency Medicine (607) Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1507) Epidemiology (15219) Forensic Medicine (30) Gastroenterology (1123) Genetic and Genomic Medicine (6584) Geriatric Medicine (667) Health Economics (997) Health Informatics (4524) Health Policy (1367) Health Systems and Quality Improvement (1611) Hematology (540) HIV/AIDS (1264) Infectious Diseases (except HIV/AIDS) (15909) Intensive Care and Critical Care Medicine (1103) Medical Education (622) Medical Ethics (145) Nephrology (667) Neurology (6585) Nursing (345) Nutrition (998) Obstetrics and Gynecology (1143) Occupational and Environmental Health (956) Oncology (3330) Ophthalmology (970) Orthopedics (369) Otolaryngology (420) Pain Medicine (435) Palliative Medicine (129) Pathology (663) Pediatrics (1690) Pharmacology and Therapeutics (691) Primary Care Research (710) Psychiatry and Clinical Psychology (5437) Public and Global Health (9218) Radiology and Imaging (2194) Rehabilitation Medicine and Physical Therapy (1369) Respiratory Medicine (1195) Rheumatology (593) Sexual and Reproductive Health (709) Sports Medicine (529) Surgery (709) Toxicology (99) Transplantation (289) Urology (265) (function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'9ff74a57fad509d6',t:'MTc3OTQwNTQwMg=='};var a=document.createElement('script');a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();